


NETWORK NOTICE

 Aetna Better Health of Kentucky 9900 Corporate Campus Drive Suite 100 Louisville, KY 40223	Date:	*INSERT*
	To	All Network Providers
	From	Provider Experience
	Subject	Q2 2021 HCPCS Updates

Please see HCPCS Code updates listed below. Forward to anyone in your organization impacted by these changes.

CODE	DESCRIPTION	EFFECTIVE DATE	CLINICAL CODER COMMENT	RECOMMEND AND APPROVED
C9074	Injection, lumasiran, 0.5 mg	4/1/2021	OXLUMO is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Less expensive alternative treatments available (e.g. high dose pyridoxine)	PA YES
C9776	Intraoperative near-infrared fluorescence imaging of major extra-hepatic bile duct(s) (e.g., cystic duct, common bile duct and common hepatic duct) with intravenous administration of indocyanine green (icg) (list separately in addition to code for primary procedure)	4/1/2021	CPB 0846 (Near-Infrared Vascular Imaging and Near-Infrared Fluorescence Imaging) indicates further research is needed to establish the true value of the technique in standard clinical practice. Similar code C9756 (Fluorescence lymph map w/ICG) ACorp PA Yes. Recommend PA Yes.	
C9777	Esophageal mucosal integrity testing by electrical impedance, transoral (list separately in addition to code for primary procedure)	4/1/2021	MiVu™ Mucosal Integrity Testing System by Diversatek Healthcare is classified as De Novo through the FDA (https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180067.pdf). This GERD testing tool is too new to determine its effectiveness. Recommend PA Yes.	PA Yes
J1427	Injection, viltolarsen, 10 mg	4/1/2021	VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Slightly less expensive than alternative Vyondys 53. Recommend PA Yes.	PA Yes

J1554	Injection, immune globulin (asceniv), 500 mg	4/1/2021	ASCENIV is indicated for the treatment of primary humoral immunodeficiency for adults and adolescents. Requires prescribers to closely monitor for black box warning symptoms: thrombosis, death, renal dysfunction, administered in a hospital setting, and test to confirm humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). Recommend PA Yes.	PA Yes
J7402	Mometasone furoate sinus implant, (sinuva), 10 micrograms	4/1/2021	SINUVA is indicated for the treatment of nasal polyps in patients >= age 18 years who have had ethmoid sinus surgery. PA recommended to confirm surgery and persistence of symptoms despite use of intranasal steroid irrigations or sprays. Aetna CPB considers mometasone furoate sinus implant Sinuva medically necessary for the treatment of recurrent nasal polyps in members age >=18 who would have had ethmoid sinus surgery and would otherwise be candidates for revision surgery and have nasal obstruction/congestion symptoms despite use of intranasal steroid irrigations or sprays. Recommend PA Yes.	PA Yes
J9037	Injection, belantamab mafodotin-blmf, 0.5 mg	4/1/2021	BLNREP is indicated for the treatment of adults who have relapsed or refractory multiple myeloma and who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Precertification to confirm 4 prior therapies. Recommend PA Yes.	PA Yes
J9349	Injection, tafasitamab-cxix, 2 mg	4/1/2021	MONJUVI is administered in combination with a REMS drug, lenalidomide, and should be administered in a facility with immediate access to emergency equipment and appropriate medical support to manage infusion reactions. It is second line treatment per NCCN guidelines and is indicated in patients not eligible for autologous stem cell transplant. Due to drug safety issues, the indication being dependent on transplant eligibility, and guideline recommendations as second line treatment precertification is recommended.	PA Yes
K1014	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control	4/1/2021	CPB 0578 (Lower Limb Prostheses). Considered medically necessary for select criteria. CMS replaced "hydraulic" with "fluid" in the description. Similar code L5856 (Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing and stance phase, includes electronic sensor(s), any type) ACORP PA Yes. Recommend PA Yes.	PA Yes

K1016	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve	4/1/2021	Monarch external Trigeminal Nerve Stimulation (eTNS) System by NeuroSigma received FDA approval in 2019 for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). CPB 0426 (ADHD) indicates there is currently insufficient evidence to support the use of eTNS for the treatment of ADHD. MCG A-0507 (Functional Electrical Stimulation) indicates multiple criteria are inconclusive or have non-supportive evidence of effectiveness and state further research is necessary. Similar code E0770 (Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified) ACORP PA Yes. Recommend PA Yes.	PA Yes
K1018	External upper limb tremor stimulator of the peripheral nerves of the wrist	4/1/2021	Cala Health, Inc.'s Cala Trio™ device includes two components: (1) a rechargeable stimulator with base unit and (2) a wrist-worn connector. FDA cleared Cala Trio™ to treat essential/action tremors in 2020. There is currently insufficient evidence to support the use of this device as clinical trials were expected to start late in 2020. Recommend PA Yes.	PA Yes
K1020	Non-invasive vagus nerve stimulator	4/1/2021	Electrocore, Inc.'s GammaCore Sapphire D is an external device that stimulates the cervical branch of the vagus nerve to reduce frequency of episodic cluster headaches (eCH). CPB 0191 (Vagus Nerve Stimulation) considers vagus nerve electrical stimulators and transcutaneous vagus nerve stimulation E/I for the treatment of cluster headaches. Hayes rating (5/2020): D2 for the acute treatment of eCH or chronic cluster headaches (cCH). Recommend PA Yes.	PA Yes
Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	4/1/2021	TECARTUS is indicated for the treatment of relapsed, refractory mantle cell lymphoma. In a phase 2 single arm open label multicenter trial of 68 patients with relapsed MCL, there was a 87% objective response rate, including 67% complete response. Duration of response ranged from 1-29 months. Recommend PA Yes.	PA Yes
S1091	Stent, non-coronary, temporary, with delivery system (propel)	4/1/2021	PROPEL® Sinus Implant by Intersect ENT®, Inc. is a non-surgical, corticosteroid-eluting stent. The code was decoupled from SINUVA J7402 because it is a device, not a drug. CPB 0840 (Devices for Post-Op Use Following Endoscopic Sinus Surgery) considers the use of a Propel sinus implant for maintaining sinus ostial patency following sinus surgery E/I because its effectiveness has not been established. Hayes rating (9/2020): C for treatment of chronic rhinosinusitis in adults. Recommend PA Yes.	PA Yes

Questions?

Simply contact your Network Relations Manager. Our most current listing is attached, the listing can also be found on our website.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from Aetna. There are numerous ways you may opt-out: The recipient may fax the opt-out request to 1-888-263-9488, at any time, 24 hours a day/7 day a week. The recipient may also send an opt-out request via email to do_not_call@aetna.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to Aetna to send facsimile advertisements to such person/entity at that particular number. Aetna is required by law to honor an opt-out request within thirty days of receipt. An opt out request will not opt you out of purely informational, non-advertisements, such as prior authorization requests and notices.



Aetna Better Health® of Kentucky


NETWORK RELATIONS CONTACT INFORMATION & COVERAGE AREAS

Aetna Better Health of Kentucky takes great pride in our network of physicians and related professionals who serve our members with the highest level of quality care and service. We are committed to making sure our providers receive the best and latest information, technology, and tools available to ensure their success and their ability to provide for our members. We focus on operational excellence, constantly striving to eliminate redundancy and streamline processes for the benefit and value of all our partners. Our Network Relations Team is assigned to designated areas throughout the state and are located within the communities in which they serve.

Aetna Better Health of Kentucky also offers a provider services line which can be reached by calling 1-855-300-5528 - Monday through Friday 7 AM-7 PM.

	<p>Supporting Kentucky Youth - Statewide</p> <p>Region 3 Behavioral Health Providers</p> <p>All Regions - Community Mental Health Centers</p>	<p>Dustin Johnson SKY Network Manager 502-648-6526 Johnsond38@Aetna.com</p>
<p>Behavioral Health Providers</p> <p>Region 5 Region 6 Region 7 Region 8</p>		<p>Holly Smith Network Relations Manager 815-641-7411 Smithh3@Aetna.com</p>
	<p>Association of Primary Care Physicians (APCP) Community Health Partners Cooperative Care Network Ephraim McDowell Kentucky Primary Care Association (KPCA) The Physicians Network (TPN)</p>	<p>Sammie Asher Network Relations Manager 606-401-1573 Ashers@Aetna.com</p>

Baptist Health System
King's Daughters Medical System
LifePoint Health System
Norton Healthcare System
St. Claire Medical Center
University of Kentucky System
University of Louisville System



Trista Gibson
Network Manager
606-305-2705
GibsonT1@Aetna.com



Supporting Kentucky Youth, SKY Liaison
Statewide

Michelle Marris
Network Relations
Manager, SKY Liaison
859-221-4737
MarrisM@Aetna.com

Regions 1
Ballard, Caldwell, Calloway, Carlisle, Crittenden, Fulton,
Graves, Hickman, Livingston, Lyon, McCracken
Regions 2
Christian, Daviess, Hancock, Henderson, Hopkins, McLean,
Muhlenberg, Ohio, Todd, Trigg, Union, Webster



Providers in the state of Indiana

Gina Gullo
Network Relations Manager
502-612-9958
Rlgullo@Aetna.com



Region 3
Breckinridge, Bullitt, Carroll, Grayson, Hardin, Henry,
Jefferson, Larue, Marion, Meade, Nelson, Oldham, Shelby,
Spencer, Trimble, Washington

Connie Edelen
Network Relations Manager
502-240-2122
Czedelen@Aetna.com

Region 4
Adair, Allen, Barren, Butler, Casey, Clinton, Cumberland,
Edmonson, Green, Hart, Logan, McCreary, Metcalfe, Monroe,
Pulaski, Russell, Simpson, Taylor, Warren, Wayne



Providers in the state of Tennessee

Abbi Wilson
Network Manager
270-816-0893
Wilsona8@Aetna.com



Region 5
Anderson, Bourbon, Boyle, Clark, Estill, Fayette, Franklin,
Garrard, Harrison, Jackson, Jessamine, Lincoln, Madison,
Mercer, Montgomery, Nicholas, Owen, Powell, Rockcastle,
Scott, Woodford

All other states excluding: IN, OH, TN, VA, & WV

Becky Bowman
Network Relations Manager
502-214-0399
BowmanB@Aetna.com



Region 6
Boone, Campbell, Gallatin, Grant, Kenton, Pendleton

CHI Saint Joseph Medical Group (Kentucky One)

Providers in the state of Ohio and West Virginia

Jacquelyne Pack
Network Manager
606-331-1075
Jmpack@Aetna.com

Region 8
Bell, Breathitt, Clay, Floyd, Harlan, Johnson, Knott, Knox, Laurel, Lee, Leslie, Letcher, Magoffin, Martin, Owsley, Perry, Pike, Whitley, Wolfe

Region 7
Bath, Boyd, Bracken, Carter, Elliot, Fleming, Greenup, Lawrence, Lewis, Mason, Menifee, Morgan, Robertson, Rowan


Providers in the state of Virginia



Krystal Risner
Network Manager
606-687-0310
Risnerk@Aetna.com

Save time by accessing our online resources.

Be sure to check out our convenient web tools, available 24/7.



Health Plan Website

The health plan website is a resource for members and providers. Providers will find information such as the member handbook, provider manual and the formulary on the health plan website



Visit the Website at: [AetnaBetterHealth.com/Kentucky](https://www.AetnaBetterHealth.com/Kentucky)